Close Menu

Myconostica

Irish clinical diagnostics company Trinity Biotech has acquired the blood bank screening and certain molecular assets of UK-based personalized medicine and clinical diagnostics firm Lab21, the companies said today.

BD Diagnostics, a segment of Becton Dickinson, and Lab 21 will develop the real-time PCR-based test as an in vitro diagnostic product.

The acquisition gives Lab21 access to its first set of nucleic acid-based assays, including a growing menu of RT-PCR and microarray-based tests.

The acquisition will provide Lab21 with its first nucleic acid-based assays.

Myconostica announces positive study results for MycAssay Pneumocystis and MycAssay Aspergillus assays; Exiqon reports positive results for MiRcury LNA Universal RT microRNA PCR test for colorectal cancer.

Gen-Probe's Prodesse ProAdeno+ assay; Myconostica's MycAssay Aspergillus test; Warnex launches Septin9 test in Canada.

A Myconostica official said this week that the company will debut a MycArray Mold ID array by the beginning of 2012 that will be designed to identify different species of microscopic fungi.

Myconostica presents study data for MycAssay Pneumocystis test, Transgenomic launches CE IVD-labeled K-RAS kit in EU

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.